- Khure Health reported year-over-year revenue growth in excess of 50 per cent
- In 2022, Khure Health plans to implement a cloud-based version of its platform through which physicians would be able to instantly screen a complex patient’s medical records against rare disease algorithms during the visit
- MCI Onehealth is a healthcare technology company
- MCI Onehealth (TSX:DRDR) is up by 1.41 per cent and trading at $1.43 CAD per share at 4:19 PM EST
MCI Onehealth’s subsidiary, Khure Health, achieved several milestones in 2021.
Khure Health reported year-over-year revenue growth in excess of 50 per cent including the integration of AI-enabled algorithms to screen more than 80 rare diseases into its platform and the completion of more than five million patient screenings.
In 2022, Khure Health plans to implement a cloud-based version of its platform through which physicians would be able to instantly screen a complex patient’s medical records against rare disease algorithms during the visit.
Dr. Alexander Dobranowski, MD and CEO of MCI Onehealth, commented the following:
“With our milestone of 100 rare disease algorithms on Khure’s platform in sight this quarter, a new cloud-based version of the platform that will help unlock additional high-margin opportunities in the big data sector.”
Don Watts, President of Khure Health, released a statement.
“Khure Health enables better patient outcomes through applied innovation, including through supporting earlier diagnosis and opportunities for patients to more quickly benefit from clinical discoveries.”
MCI Onehealth is a healthcare technology company focused on connecting patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs.
Khure Health is a clinical platform that allows physicians to maximize the effectiveness of medical testing.
MCI Onehealth (TSX:DRD) is up by 1.41 per cent and trading at $1.43 CAD per share at 4:19 PM EST.